
Just over three years ago I think I said the same thing: “One down.” Little did I know how difficult and, in many ways, magical the road would be. Today, the last day of this first course of the investigational Aurora A Kinase inhibitor, Patrick awoke unable to walk without significant pain. He is apparently suffering from hand and foot syndrome, which is a known side effect of chemotherapy and kinase inhibitors in particular. Fortunately, his pain is controlled with Tylenol III. We learned through research today that emollients and maybe vitamin B6 can help. We will discuss this issue with Dr. Maris and do all we can to maintain his current dose. To put this small matter in perspective, we are together at home (not a subset in NYC), not nauseated (like recent chemo), not on dilaudid (like 3F8 induced neuropathy), without port access, and otherwise doing well. The very good news is that Patrick’s CBC was unchanged from Monday. His hemoglobin, platelets, and absolute neutrophil count were great – as in normal for you and me. We only hope the drug was much more punitive of NB cells. We look forward to the MIBG scan! SRC
It is a VERY good thing for Patrick’s to be normal, and we pray for those normal results to continue for a long time. It looks like we will have MIBG and MRI scans in June, so you will be receiving “scanxiety” updates in the near future.
blessed to have an amazing community of friends, an enthusiastic staff at Druid HIlls, and a lot of new childhood cancer research advocates that we befriended this weekend. Thank you to everyone who played or donated to the cause!!!!
researchers who are investigating exciting treatment options that they believe could help save more children with neuroblastoma. MSKCC is working on several pioneering treatments including a humanized version of the 3F8 antibody, a mouse-based 3F8 antibody that attaches to neuroblastoma cells and kills them. The antibody, developed by MSKCC’s Dr. Cheung, also trains a child’s immune system to attack and kill neuroblastoma. Since first used in 1987, 3F8 treatment has greatly improved survival without lasting side effects. The mouse-based antibody’s primary drawback is that it can be rejected by the child’s own immune system. MSKCC is researching chimeric and humanized v ersions of 3F8 to alleviate this issue and make it more effective for a greater number of patients. MSKCC is also workng on several other promising treatments for neuroblastoma, including different antibodies and a vaccine.
we will not know that for sure without further testing. We are deeply saddened, but gearing up for another full attack on the beast neuroblastoma. We have not told the children and don’t plan to do so until we cannot keep it from them any longer. Patrick will have another MIBG scan tomorrow, and we will meet with Dr. Katzenstein afterwards. We are trying to schedule CT and MRI scans and likely bone marrows and a lumbar puncture so that we can determine exactly the extent of his disease. I will keep everyone posted as we receive the news.
Erin and I took Patrick for the 48 hour MIBG and CT this morning. We just got home. When I saw the spot light up on his head I could not imagine how Erin felt when she saw it yesterday without preparation. The equivocal spot in the chest remains equivocal. If it is there it is very small. The CT of the head clearly showed a bony lesion – not an intracranial lesion. It is easily targeted with radiation. Bone marrow biopsies are scheduled for Tuesday; port implantation for late next week. Assuming the bone marrow is clear (please specifically pray for that), then the plan will include simultaneous chemotherapy (irinotecan and temodar) and radiation for essentially two weeks beginning a week from Monday. This treatment will be outpatient, but the days will be long and tough. He will then be off for two or three weeks, then another round of the same chemo, then we will re-scan. The goal is to achieve second remission as soon as possible. Meanwhile we will plan a maintenance regimen. Those options are many, but the choice is complicated. We are entering the world of experimental therapy in a big way. Doctors at CHOA, Sloan Kettering, CHOP, MD Anderson, Vermont, and UC San Diego are already on Patrick’s team. We will not be out-smarted or out-worked. We will continue to smile and live a fun life.